EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adverse events in small dogs treated with a single dose of vinblastine

Fukiko Matsuyama, Kei Harada, Masanao Ichimata, Eri Fukazawa, Ryuzo Katayama, Tetsuya Kobayashi

Journal of Veterinary Internal Medicine · 02.03.2026 · 40 (2)

DOI: 10.1093/jvimsj/aalag050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, online erschienen am 30.03.2026. Verfasst von Fukiko Matsuyama und 5 weiteren Autor:innen. Beteiligte Einrichtung: Japan Small Animal Cancer Center, Japan Small Animal Medical Center, 1-10-4, Higashitokorozawa wada, Tokorozawa-shi, Saitama 359-0023, Japan. Hauptthemen laut MEDLINE: Vinblastine, Neoplasms, Dog Diseases. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vinblastine (VBL) is a chemotherapeutic agent commonly used to treat malignant tumors in dogs. Although a maximum tolerated dose of 3.5 mg/m2 has been reported, the safety and tolerability of this dose in small dogs remain inadequately characterized. Hypothesis/Objectives Retrospectively evaluate adverse events (AEs) associated with a single IV administration of VBL at a dosage of 2.0 mg/m2 in dogs weighing < 10 kg. We hypothesized that AE occurrences in small dogs would be comparable to those reported in phase I studies involving larger breeds. Animals Forty client-owned dogs weighing < 10 kg with malignant tumors.

Methods

Adverse events after a single IV VBL administration at a dosage of 2.0 mg/m2 were retrospectively evaluated in small dogs with malignant tumors. Myelosuppressive and gastrointestinal AEs were graded using VCOG-CTCAE v2.0 criteria.

Results

Neutropenia and thrombocytopenia were observed in 82.5% (33/40) and 5.0% (2/40) of dogs, respectively. Grade 3 or 4 neutropenia occurred in 32.5% (13/40), comprising 15.0% (6/40) with Grade 3 and 17.5% (7/40) with Grade 4 events. Inappetence, vomiting, and diarrhea were reported in 7.5% (3/40), 7.5% (3/40), and 25.0% (10/40) of dogs, respectively, and were generally mild. Febrile neutropenia was noted in 5.0% (2/40) of dogs. Conclusions and clinical importance Vinblastine administered at a dosage of 2.0 mg/m2 in small dogs with malignant tumors resulted in gastrointestinal toxicity within clinically acceptable limits, but close monitoring for neutropenia is warranted. These findings suggest that dose escalation of VBL, as reported in larger dogs, may not be feasible in smaller dogs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VinblastineNeoplasmsDog DiseasesAnimalsDogsRetrospective StudiesNeutropeniaThrombocytopeniaBody Weight

Stichwörter der Autor:innen

adverse eventsdose intensityfebrile neutropeniasmall dogsvinblastine

Substanzen

Vinblastine

Autor:innen und Institutionen

  • Japan Small Animal Cancer Center, Japan Small Animal Medical Center, 1-10-4, Higashitokorozawa wada, Tokorozawa-shi, Saitama 359-0023, Japan.

Zitieren

APA

Matsuyama, F., Harada, K., Ichimata, M., Fukazawa, E., Katayama, R., & Kobayashi, T. (2026). Adverse events in small dogs treated with a single dose of vinblastine. Journal of Veterinary Internal Medicine, 40(2). https://doi.org/10.1093/jvimsj/aalag050

Vancouver

Matsuyama F, Harada K, Ichimata M, Fukazawa E, Katayama R, Kobayashi T. Adverse events in small dogs treated with a single dose of vinblastine. Journal of Veterinary Internal Medicine. 2026;40(2). doi:10.1093/jvimsj/aalag050

BibTeX
@article{Matsuyama2026,
  author = {Matsuyama, Fukiko and Harada, Kei and Ichimata, Masanao and Fukazawa, Eri and Katayama, Ryuzo and Kobayashi, Tetsuya},
  title = {Adverse events in small dogs treated with a single dose of vinblastine},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2026},
  volume = {40},
  number = {2},
  doi = {10.1093/jvimsj/aalag050}
}
Kostenlos starten →